Zinc deficiency alters responsiveness to antidepressant drugs in mice

Pharmacological Reports

Volumn 65, Issue 3, 2013, Pages 579-592

  Młyniec, Katarzyna ^a,b   Budziszewska, Bogusława ^a,b   Reczyński, Witold ^c   Doboszewska, Urszula ^b   Pilc, Andrzej ^a,b   Nowak, Gabriel ^a,b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c AGH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Poland)

Author keywords

Antidepressants; Corticosterone; Depression; Stress; Zinc; Zinc deficiency

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CORTICOSTERONE; ESCITALOPRAM; IMIPRAMINE; REBOXETINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DISEASE DURATION; DOSE RESPONSE; DRUG RESPONSE; FORCED SWIMMING TEST; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IMMOBILITY; LOCOMOTION; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; RADIOIMMUNOASSAY; ZINC BLOOD LEVEL; ZINC DEFICIENCY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; CORTICOSTERONE; DEPRESSION; DIET; DISEASE MODELS, ANIMAL; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MICE; MOTOR ACTIVITY; PITUITARY-ADRENAL SYSTEM; SWIMMING; ZINC;

EID: 84884490256     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71035-1     Document Type: Article

References (72)

1. Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ: Safety and efficacy of repeated-dose intravenous ketamine for treatmentresistant depression. Biol Psychiatry, 2010, 67, 139-145.
2. Berlim MT, Turecki G: What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials. Eur Neuropsychopharmacol, 2007, 17, 696-707. (Pubitemid 47422400)
3. Brown KH, Wuehler SE, Peerson JM: The importance of zinc in human nutrition and estimation of the global prevalence of zinc deficiency. Food Nutr Bull, 2001, 22, 113-125. (Pubitemid 32653119)
4. Castagné V, Moser P, Roux S, Porsolt RD: Rodent models of depression: forced swim and tail suspension behavioral despair tests in rats and mice. Curr Protoc Neurosci, 2011, Chapter 8: Unit 8.10 A.
5. Chasapis CT, Loutsidou AC, Spiliopoulou CA, Stefanidou ME: Zinc and human health. An update. Arch Toxicol, 2012, 86, 521-534.
6. Cieoelik K, Klenk-Majewska B, Danilczuk Z, Wróbel A, Łupina T, Ossowska G: Influence of zinc suplementation on imipramine effect in a chronic unpredictable stress (CUS) model in rats. Pharmacol Rep, 2007, 59, 46-52. (Pubitemid 46522701)
7. Cieoelik K, Sowa-Kućma M, Ossowska G, Legutko B, Wolak M, Opoka W, Nowak G: Chronic unpredictable stress-induced reduction in the hippocampal brainderived neurotrophic factor (BDNF) gene expression is antagonized by zinc treatment. Pharmacol Rep, 2011, 63, 537-543.
8. Cousins RJ, Dunn MA, Leinart AS, Yedinak KC, DiSilvestro RA: Coordinate regulation of zinc metabolism and metallothionein gene expression in rats. Am J Physiol, 1986, 251, 688-694.
9. Covvey JR, Crawford AN, Lowe DK: Intravenous ketamine for treatment-resistant major depressive disorder. Ann Pharmacother, 2012, 46, 117-123.
10. Cunha MP, Machado DG, Bettio LEB, Capra JC, Rodrigues ALS: Interaction of zinc with antidepressants in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry, 32, 2008, 1913-1920.
11. Dhir A, Kulkarni SK: Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol, 2007, 568, 177-185. (Pubitemid 46976903)
12. Dhir A, Kulkarni SK: Nitric oxide and major depression. Nitric Oxide, 2011, 24, 125-31.
13. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA et al.: A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry, 2010, 67, 793-802.
14. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G: Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology, 2012, 62, 35-41.
15. Fava M: Diagnosis and definition of treatment-resistant depression. Biol Psychiatry, 2003, 53, 649-659. (Pubitemid 39658481)
16. Fava M, Davidson KG: Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am, 1996, 19, 179-200.
17. Hamon M, Bourgoin S: Pharmacological profile of antidepressants: a likely basis for their efficacy and side effects? Eur Neuropsychopharmacol, 2006, 16, 625-632.
18. Hashimoto K: Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev, 2009, 61, 105-123.
19. Hashimoto K: The role of glutamate on the action of antidepressants. Prog. Neuropsychopharmacol Biol Psychiatry, 2010, 35, 1558-1568.
20. Kroczka B, Branski P, Palucha A, Pilc A, Nowak G: Antidepressant-like properties of zinc in rodent forced swim test. Brain Res Bull, 2001, 55, 297-300. (Pubitemid 32722173)
21. Kroczka B, Zie{ogonek}ba A, Dudek D, Pilc A, Nowak G: Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol J Pharmacol, 2000, 52, 403-406.
22. Levenson CW: Zinc: The new antidepressant? Nutr Rev 2006, 64, 39-42.
23. Maes M, De Vos N, Demedts P, Wauters A, Neels H: Lower serum zinc in major depression in relation to changes in serum acute phase proteins. J Affect Disord, 1999, 56, 189-194. (Pubitemid 30058221)
24. Maes M, D'Haese PC, Scharpé S, D'Hondt P, Cosyns P, De Broe ME: Hypozincemia in depression. J Affect Disord 1994, 31, 135-140. (Pubitemid 24183901)
25. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord, 1995, 34, 301-309.
26. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyder R: Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry, 1997, 42, 349-358. (Pubitemid 27380969)
27. Mathew SJ, Murrough JW, Aan Het Rot M, Collins KA, Reich DL, Charney DS: Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol, 2010, 13, 71-82.
28. Mathew SJ, Shah A, Lapidus K, Clark C, Jarun N, Ostermeyer B, Murrough JW: Ketamine for treatmentresistant unipolar depression: current evidence. CNS Drugs, 2012, 26, 189-204.
29. McLoughlin IJ, Hodge JS: Zinc in depressive disorder. Acta Psychiatr Scand, 1990, 82, 451-453.
30. Młyniec K, Davies CL, Budziszewska B, Opoka W, Reczyński W, Sowa-Kućma M, Doboszewska U et al.: Time course of zinc deprivation-induced alterations of mice behavior in the forced swim test. Pharmacol Rep, 2012, 64, 567-575.
31. Młyniec K, Nowak G: Zinc deficiency induces depression-like behavior in the tail suspension test in mice. Pharmacol Rep, 2012, 64, 249-255.
32. Musazzi M, Racagni G, Popoli M: Stress, glucocorticoids and glutamate release: Effects of antidepressant drugs. Neurochem Int, 2011, 59, 138-149.
33. Nowak G, Schlegel-Zawadzka M: Alterations in serum and brain trace element levels after antidepressant treatment: part I. Zinc. Biol Trace Elem Res, 1999, 67, 85-92. (Pubitemid 29094235)
34. Nowak G, Siwek M, Dudek D, Zie{ogonek}ba A, Pilc A: Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol, 2003, 55, 1143-1147. (Pubitemid 38128954)
35. Nowak G, Szewczyk B, Pilc A: Zinc and depression. An update. Pharmacol Rep, 2005, 57, 713-718.
36. Nowak G, Szewczyk B, Wieronska JM, Branski P, Palucha A, Pilc A, Sadlik K, Piekoszewski W: Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res Bull, 2003, 61, 159-164. (Pubitemid 36794273)
37. Nowak G, Zieba A, Dudek D, Krosniak M, Szymaczek M, Schlegel-Zawadzka M: Serum trace elements in animals models and human depression. Part I. Zinc. Hum Psychopharmacol Clin Exp, 1999, 14, 83-86. (Pubitemid 29139914)
38. Paoletti P, Ascher P, Neyton J: High-affinity zinc inhibition of NMDA NR1-NR2 receptors. J Neurosci, 1997, 17, 5711-5725. (Pubitemid 27310487)
39. Pennix BW, Kritchevsky SB, Yaffe K, Newman AB, Simonsick EM, Rubin S, Ferrucci L et al.: Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study. Biol Psychiatry, 2003, 54, 566-572. (Pubitemid 37289443)
40. Porsolt RD, Bertin A, Jalfre M: Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther, 1977, 229, 327-336. (Pubitemid 8225714)
41. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW: An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol, 2008, 28, 631-637.
42. Rosa AO, Lin J, Calixto JB, Santos ARS, Rodrigues ALS: Involvement of NMDA receptors and L-argininenitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res, 2003, 144, 87-93. (Pubitemid 37011169)
43. Rush AJ, Thase ME, Dube S: Research issues in the study of difficult-to-treat depression. Biol Psychiatry, 2003, 53, 743-753. (Pubitemid 39658488)
44. Sanacora G, Treccani G, Popoli M: Towards a glutamate hypothesis of depression: An emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology, 2012, 62, 63-77.
45. Siwek M, Dudek D, Paul IA, Sowa-Kucma M, Zieba A, Popik P, Pilc A, Nowak G: Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord, 2009, 118, 187-195.
46. Siwek M, Dudek D, Schlegel-Zawadzka M, Morawska A, Piekoszewski W, Opoka W, Zieba A et al.: Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J Affect Disord, 2010, 126, 447-452.
47. Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol, 1999, 375, 31-40. (Pubitemid 29317590)
48. Skolnick P, Layer RT, Popik P, Nowak G, Paul IA, Trullas R: Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression. Pharmacopsychiatry, 1996, 29, 23-26. (Pubitemid 26072654)
49. Skolnick P, Popik P, Trullas R: Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci, 2009, 30, 563-569.
50. Sluzewska A, Rybakowski JK, Laciak M, Mackiewicz A, Sobieska M, Wiktorowicz K: Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci, 1995, 762, 474-476.
51. Souery D, Amsterdam J, De Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G et al.: Treatmentresistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol, 1999, 9, 83-91. (Pubitemid 29073687)
52. Sowa-Kućma M, Legutko B, Szewczyk B, Novak K, Znojek P, Poleszak E, Papp M et al.: Antidepressant-like activity of zinc: further behavioural and molecular evidence. J Neural Transm, 2008, 115, 1621-1628.
53. Soygur H, Palaoglu O, Akarsu ES, Cankurtaran ES, Ozalp E, Turhan L, Ayhan IH: Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry, 2007, 31, 1242-1247. (Pubitemid 47081310)
54. Szewczyk B, Palucha-Poniewiera A, Poleszak E, Pilc A, Nowak G: Investigational NMDA receptor modulators for depression. Expert Opinion on Investig Drugs, 2012, 21, 91-102.
55. Szewczyk B, Poleszak E, Sowa-Kućma M, Siwek M, Dudek D, Ryszewska-Pokraoeniewicz B, Radziwoń-Zaleska M et al.: Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action. Pharmacol Rep, 2008, 60, 588-599.
56. Szewczyk B, Poleszak E, Wlaź P, Wróbel A, Blicharska E, Cichy A, Dybala M et al.: The involvement of serotonergic system in the antidepressant effect of zinc in the forced swim test. Progr Neuropsychopharmacol Biol Psychiatry, 2009, 33, 323-329.
57. Takeda A, Tamano H: Zinc signaling through glucocorticoid and glutamate signaling in stressful circumstances. J Neurosci Res, 2010, 88, 3002-3010.
58. Takeda A, Tamano H, Itoh H, Oku N: Attenuation of abnormal glutamate release in zinc deficiency by zinc and Yokukansan. Neurochem Int, 2008, 53, 230-235.
59. Takeda A, Tamano H, Kan F, Itoh H, Oku N: Anxietylike behavior of young rats after 2-week zinc deprivation. Behav Brain Res, 2007, 177, 1-6. (Pubitemid 46054205)
60. Takeda A, Tamano H, Ogawa T, Takada S, Ando M, Oku N, Watanabe M: Significance of serum glucocorticoid and chelatable zinc in depression and cognition in zinc deficiency. Behav Brain Res, 2012, 226, 259-254.
61. Takeda A, Tamano H, Tochigi M, Oku N: Zinc homeostasis in the hippocampus of zinc-deficient young adult rats. Neurochem Int, 2005, 46, 221-225.
62. Takeda A, Yamada K, Tamano H, Fuke S, Kawamura M, Oku N: Hippocampal calcium dyshomeostasis and longterm potentiation in 2-week zinc deficiency. Neurochem Int, 2008, 241-246. (Pubitemid 350235696)
63. Tamano H, Kan F, Kawamura M, Oku N, Takeda A: Behavior in the forced swim test and neurochemical changes in the hippocampus in young rats after 2-week zinc deprivation. Neurochem Int, 2009, 55, 536-541.
64. Tassabehji NM, Corniola RS, Alshingiti A, Levenson CW: Zinc deficiency induces depression-like symptoms in adult rats. Physiol Behav, 2008, 95, 365-369.
65. Trullas R, Skolnick P: Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol, 1990, 185, 1-10. (Pubitemid 20254891)
66. Van Den Eede F, Claes SJ:Mechanisms of depression: role of the HP Aaxis. Drug Discov Today, 2004, 1, 413-418.
67. Vetulani J, Nalepa I: Antidepressants: past, present and future. Eur J Pharmacol, 2000, 405, 351-363.
68. Watanabe M, Tamano H, Kikuchi T, Takeda A: Susceptibility to stress in young rats after 2-week zinc deprivation. Neurochem Int, 2010, 56, 410-416.
69. Whittle N, Lubec G, Singewald N: Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice. Amino Acids, 2009, 36, 147-158.
70. Wójcik J, Dudek D, Schlegel-Zawadzka M, Grabowska M, Marcinek A, Florek E, Piekoszewski W et al.: Antepartum/postpartum depressive symptoms and serum zinc and magnesium levels. Pharmacol Rep, 2006, 58, 571-576. (Pubitemid 44383284)
71. Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry, 2004, 161, 171-174. (Pubitemid 38419327)
72. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006, 63, 856-864. (Pubitemid 44188478)